Literature DB >> 27519196

Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia.

L Ose1, R Scott2, L Grossman3.   

Abstract

The clinical efficacy and tolerability of simvastatin and fluvastatin were compared in 432 patients with primary hypercholesterolaemia in a multinational, randomised, double-blind trial. Following at least 10 weeks on a lipid-lowering diet, patients continuing to have a total cholesterol level ≥ 6.5 mmol/L and elevated low density lipoprotein (LDL) cholesterol levels received 6 weeks of once-daily treatment with either simvastatin 5mg (n = 109), simvastatin 10mg (n =110), fluvastatin 20mg (n = 105), or fluvastatin 40mg (n = 108). The relative potency rates of simvastatin to fluvastatin in reducing LDL and total cholesterol levels were estimated to be 7.60 and 7.65, respectively. Significantly greater mean reductions in LDL cholesterol levels were found at week 6 with simvastatin 10mg (30%) compared with either fluvastatin 20mg (22%; p < 0.001) or fluvastatin 40mg (26%; p = 0.03). Similarly, LDL cholesterol was lowered more in the simvastatin 5mg group (26%) than in the fluvastatin 20mg group (22%; p = 0.03). No significant difference was seen between simvastatin 5mg and fluvastatin 40mg. Plasma total cholesterol levels were also significantly lower with simvastatin 10mg compared with fluvastatin 20mg (23 vs 16%; p < 0.001) and fluvastatin 40mg (23 vs 19%; p = 0.02), and with simvastatin 5mg compared with fluvastatin 20mg (19 vs 16%; p = 0.01). Simvastatin 5mg and fluvastatin 40mg both lowered total cholesterol levels by 19%. The percentage of patients reaching National Cholesterol Education Program Adult Treatment Panel II (NCEP ATP II) target LDL cholesterol levels after 6 weeks' treatment with simvastatin 5 or 10 mg/day or fluvastatin 20 or 40 mg/day was 24, 25, 12 and 21%, respectively. Tolerability profiles were generally similar, although significantly more gastrointestinal adverse events occurred in the fluvastatin-treated patients (23 vs 11%). In conclusion, simvastatin 10 mg/day is more effective in lowering total and LDL cholesterol levels than the maximum recommended dose of fluvastatin (40 mg/day), whereas simvastatin 5 mg/day and fluvastatin 40 mg/day showed similar efficacy.

Entities:  

Year:  1995        PMID: 27519196     DOI: 10.2165/00044011-199510030-00001

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  15 in total

1.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

2.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Authors: 
Journal:  JAMA       Date:  1993-06-16       Impact factor: 56.272

3.  Clinical implications of the biopharmaceutical properties of fluvastatin.

Authors:  J P Deslypere
Journal:  Am J Cardiol       Date:  1994-05-26       Impact factor: 2.778

Review 4.  A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.

Authors:  R I Levy; A J Troendle; J M Fattu
Journal:  Circulation       Date:  1993-04       Impact factor: 29.690

5.  Cholesterol and mortality. 30 years of follow-up from the Framingham study.

Authors:  K M Anderson; W P Castelli; D Levy
Journal:  JAMA       Date:  1987-04-24       Impact factor: 56.272

6.  Cholesterol lowering and the reduction of CHD incidence and total mortality: results from a meta-analysis of randomized trials.

Authors:  I Holme
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

7.  Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study.

Authors:  M R Law; N J Wald; T Wu; A Hackshaw; A Bailey
Journal:  BMJ       Date:  1994-02-05

8.  Fluvastatin reduces levels of plasma apo B-containing particles and increases those of LpA-I. European Fluvastatin Study Group.

Authors:  J Dallongeville; J C Fruchart; P Pfister; J M Bard
Journal:  Am J Med       Date:  1994-06-06       Impact factor: 4.965

9.  Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine.

Authors:  E Hagen; H Istad; L Ose; E Bodd; H M Eriksen; V Selvig; J M Bard; J C Fruchart; M Borge; M C Wolf
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

10.  Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)

Authors: 
Journal:  Lancet       Date:  1994-09-03       Impact factor: 79.321

View more
  5 in total

Review 1.  Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.

Authors:  G L Plosker; A J Wagstaff
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 2.  Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Authors:  H Lennernäs; G Fager
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

Review 3.  Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.

Authors:  T R Pedersen; J A Tobert
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

Review 4.  Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.

Authors:  G L Plosker; D McTavish
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 5.  Fluvastatin for lowering lipids.

Authors:  Stephen P Adams; Sarpreet S Sekhon; Michael Tsang; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2018-03-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.